Patent: 9,879,088
✉ Email this page to a colleague
Summary for Patent: 9,879,088
Title: | Disease therapy by inducing immune response to Trop-2 expressing cells |
Abstract: | The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-.alpha.), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2.sup.+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC. |
Inventor(s): | Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Rossi; Edmund A. (Woodland Park, NJ), Rossi; Diane (Woodland Park, NJ) |
Assignee: | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) |
Application Number: | 15/497,931 |
Patent Claims: | see list of patent claims |
Details for Patent 9,879,088
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2032-08-14 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2032-08-14 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2032-08-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |